Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
FDA guidelines consider amyloid reduction 'reasonably likely' to predict Alzheimer's benefit
Fierce Biotech
Tue, 03/12/24 - 11:34 am
Biogen
Eisai
Aduhelm
FDA
Alzheimer's disease
amyloid
Eli Lilly
donanemab
Tau, anti-inflammation and orals form Biogen's future Alzheimer's pipeline
Fierce Biotech
Thu, 03/7/24 - 11:38 am
Biogen
Alzheimer's disease
anti-tau antibodies
anti-inflammatory
Eisai
Leqembi
Biogen relying on success of Leqembi following discontinuation of Aduhelm
Biopharma Reporter
Mon, 03/4/24 - 11:19 am
Biogen
Leqembi
Aduhelm. Alzheimer's disease
Biogen partner NeuroSense seeks a role in the ALS revolution
Pharma Voice
Fri, 03/1/24 - 11:24 am
NeuroSense Therapeutics
Biogen
ALS
EU medicines regulator backs Biogen's ALS drug
Reuters
Fri, 02/23/24 - 10:28 am
Biogen
Europe
ALS
Qalsody
Biogen gets DOJ subpoena on business operations in foreign countries
Reuters
Wed, 02/14/24 - 10:58 am
Biogen
DOJ
Biogen has a fuzzy line of sight on prized Alzheimer’s drug
BioPharma Dive
Tue, 02/13/24 - 11:16 pm
Biogen
Alzheimer's disease
Leqembi
Biogen sees flat 2024 sales, pick up in Alzheimer's drug demand
Reuters
Tue, 02/13/24 - 11:31 am
Biogen
earnings
Eisai, Biogen likely to miss early launch goal for Alzheimer's drug Leqembi
Fierce Pharma
Wed, 02/7/24 - 11:33 am
Eisai
Biogen
FDA
Medicare
Leqembi
Alzheimer's disease
Biogen abandons Aduhelm efforts, focuses on Eisai-partnered Leqembi and pipeline drugs
Fierce Pharma
Wed, 01/31/24 - 11:50 am
Biogen
Aduhelm
Leqembi
Alzheimer's disease
In downsizing mode, Sage will move headquarters to a smaller space
Fierce Pharma
Thu, 01/25/24 - 11:17 am
SAGE Therapeutics
headquarters
Biogen
Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda
Fierce Pharma
Thu, 01/11/24 - 08:45 pm
Biogen
Fampyra
MS
multiple sclerosis
Acorda Therapeutics
Biogen CEO sees progress in launch of Alzheimer’s drug Leqembi
BioPharma Dive
Mon, 01/8/24 - 10:22 pm
Biogen
Pharma CEOs
Chris Viehbacher
Leqembi
Alzheimer's disease
insurance
JPMHC 2024
Europe revokes marketing authorization for generic versions of Biogen's MS drug
Reuters
Tue, 12/19/23 - 10:08 am
Biogen
Tecfidera
MS
multiple sclerosis
Europe
generics
As Biogen's sales flatline, CEO Chris Viehbacher touts progress on Leqembi, Skyclarys and other launches
Fierce Pharma
Wed, 11/8/23 - 12:10 pm
Biogen
Pharma CEOs
Chris Viehbacher
earnings
Leqembi
Skyclarys
Biogen's M&A, Alzheimer's drug launch costs spark profit forecast cut
Reuters
Wed, 11/8/23 - 11:35 am
Biogen
Alzheimer's disease
Leqembi
Reata
M&A
earnings
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900
Reuters
Tue, 11/7/23 - 09:55 am
Biogen
SAGE Therapeutics
postpartum depression
drug pricing
Zurzuvae
Eisai says new data could support more convenient form of Alzheimer’s drug Leqembi
BioPharma Dive
Wed, 10/25/23 - 10:42 pm
Eisai
Biogen
Leqembi
Alzheimer's disease
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Reuters
Mon, 10/23/23 - 05:11 pm
Roche
legal
Biogen
biosimilars
Actemra
Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO
Stat
Fri, 10/20/23 - 09:57 am
Biogen
Christopher Viehbacher
Pharma CEOs
risk
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »